Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:LVTXNASDAQ:MEIPNASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.79+2.3%$6.64$5.20▼$15.60$10.85M0.9110,871 shs10,070 shsLVTXLAVA Therapeutics$1.31-2.2%$1.29$0.85▼$2.39$35.25M0.48156,071 shs15,523 shsMEIPMEI Pharma$2.20-2.2%$2.12$1.46▼$4.10N/A0.1643,219 shs13,478 shsNXTCNextCure$0.47+3.8%$0.46$0.22▼$1.82$12.70M1.07125,117 shs163,947 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+2.30%-5.08%-8.68%-34.05%-60.61%LVTXLAVA Therapeutics+1.08%0.00%-0.76%+0.77%-32.82%MEIPMEI Pharma-3.51%-3.93%+2.33%-4.35%-21.99%NXTCNextCure+3.84%-30.98%-7.19%-17.54%-64.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics2.6385 of 5 stars3.25.00.00.00.01.71.3LVTXLAVA Therapeutics1.7005 of 5 stars3.05.00.00.00.00.00.0MEIPMEI Pharma1.5369 of 5 stars0.03.00.04.10.00.81.3NXTCNextCure4.5159 of 5 stars3.55.00.04.31.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00763.56% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17141.73% UpsideMEIPMEI Pharma 2.00HoldN/AN/ANXTCNextCure 3.00Buy$3.50644.68% UpsideCurrent Analyst Ratings BreakdownLatest MEIP, BOLT, NXTC, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/15/2025LVTXLAVA TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.003/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.503/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$30.00 ➝ $25.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.45N/AN/A$29.89 per share0.19LVTXLAVA Therapeutics$11.98M2.88N/AN/A$1.06 per share1.24MEIPMEI Pharma$65.30MN/A$5.79 per share0.38$4.96 per shareN/ANXTCNextCureN/AN/AN/AN/A$2.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.04N/AN/AN/AN/A-86.38%-34.12%8/19/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)Latest MEIP, BOLT, NXTC, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LVTXLAVA Therapeutics-$0.37-$0.13+$0.24-$0.13N/AN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$7.60-$7.60N/A-$0.42$0.79 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13LVTXLAVA TherapeuticsN/A6.736.73MEIPMEI PharmaN/A16.7816.78NXTCNextCureN/A10.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%LVTXLAVA TherapeuticsN/AMEIPMEI Pharma52.38%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%LVTXLAVA Therapeutics9.50%MEIPMEI Pharma3.12%NXTCNextCure17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableMEIPMEI Pharma100N/AN/AOptionableNXTCNextCure9028.05 million23.03 millionOptionableMEIP, BOLT, NXTC, and LVTX HeadlinesRecent News About These CompaniesNextcure stock drops near 30% on $745M ADC deal with SimcereJune 18 at 5:33 AM | bioworld.comNextCure Joins China-ADC Gold Rush with $745M Simcere DealJune 17, 2025 | biospace.comNextCure tanks as it teams up with Simcere on novel ADCJune 17, 2025 | thepharmaletter.comNextCure advances ADC pivot with $745M deal for Simcere’s phase 1 drugJune 16, 2025 | fiercebiotech.comNextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% DeclineJune 16, 2025 | msn.comNextCure signs up to $745 million deal with China's Simcere to develop cancer drugJune 16, 2025 | reuters.comNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6June 16, 2025 | globenewswire.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...May 30, 2025 | morningstar.comNextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025May 30, 2025 | nasdaq.comNextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024May 30, 2025 | insidermonkey.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025May 29, 2025 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | taiwannews.com.twNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 1, 2025 | globenewswire.comNextCure to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | globenewswire.comH.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74March 17, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for NextCure (NXTC)March 8, 2025 | markets.businessinsider.comNextCure Reports 2024 Financials and Strategic ProgressMarch 7, 2025 | tipranks.comNextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill CohortsMarch 6, 2025 | quiverquant.comNextCure Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comNextCure stock plunges to 52-week low, hits $0.69February 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEIP, BOLT, NXTC, and LVTX Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.79 +0.13 (+2.30%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.84 +0.05 (+0.93%) As of 06/20/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.LAVA Therapeutics NASDAQ:LVTX$1.31 -0.03 (-2.24%) Closing price 06/20/2025 03:56 PM EasternExtended Trading$1.36 +0.04 (+3.44%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.MEI Pharma NASDAQ:MEIP$2.20 -0.05 (-2.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.23 +0.03 (+1.36%) As of 06/20/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.NextCure NASDAQ:NXTC$0.47 +0.02 (+3.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.48 +0.01 (+1.91%) As of 06/20/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
